Prime Medicine’s (PRME) “Neutral” Rating Reiterated at JPMorgan Chase & Co.
JPMorgan Chase & Co. restated their neutral rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a research report sent to investors on Tuesday morning, MarketBeat Ratings reports. Other equities analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares […]
JPMorgan Chase & Co. restated their neutral rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a research report sent to investors on Tuesday morning, MarketBeat Ratings reports. Other equities analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares […]
